Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho™ in Patients With Chronic Neutropenia

NCT02533362 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.

NCT NCT02533362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho™ in Patients With Chronic Neutropenia
Lead sponsor
Prolong Pharmaceuticals
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 31, 2015
Completion date
October 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia, severe chronic